Supplier News Breaks Archives
Actavis revamps global business organization
February 3rd, 2014
DUBLIN, Ireland – Actavis plc has realigned its global strategic business structure to reflect its stronger position in the specialty pharmaceutical space.
The company said Friday that its global generics, specialty brands, branded generics, legacy brands, over-the-counter and third-party commercial operations and business development have been consolidated into one new division led by Siggi Olafsson, president of Actavis Pharma.
Actavis' generic, brand, inhalation and biosimilars research-and-development organizations have been consolidated under the leadership of Fred Wilkinson in the newly created position of president of Actavis Global Research and Development.
Olafsson and Wilkinson will continue to report directly to Paul Bisaro, chairman and chief executive officer of Actavis.
Actavis announced the new structure as its 2014 Investor Meeting in New York.
"Over the past several years, Actavis has evolved into a leading specialty pharmaceutical company with a solid global commercial footprint and a research and development capability unmatched within the industry," stated Bisaro. "This organization will provide unprecedented management focus on driving our company to the next stage in our evolution and ensure our successful evolution into the world's premier, global specialty pharmaceutical leader."
Bisaro noted that placing all commercial pharmaceutical sales and marketing functions under Olafsson better positions Actavis to respond to global market needs and competition.
"Actavis currently participates in more than 60 markets, and we are focused on expanding our commercial footprint," he explained. "Siggi's knowledge of global markets and understanding of the intricacies of delivering pharmaceuticals that meet the needs of specific market dynamics — brand, generic, branded generic and OTC products — ensures we are capitalizing on opportunities to drive revenues and earnings growth. Combining our commercial operations will dramatically strengthen Actavis' position as a global provider of pharmaceutical products to our patients in our diverse customer base."
According to Bisaro, combining generic, brand, inhalation and biosimilar research and development, global regulatory affairs and global pharmacovigilance activities under Wilkinson enables the company to leverage his pharmaceutical industry expertise to direct and deliver on its R&D investment, expected to top $800 million in 2014.
"Fred's expertise in our core brand therapeutic categories, his management of our biosimilar initiatives and his decades-long experience in the generic pharmaceutical universe brings real-world marketing realities to ensuring new products developed achieve their full potential," Bisaro stated. "Under Fred's leadership, we will dramatically enhance our ability to deliver on a fully integrated, global pharmaceutical pipeline and ensure we maximize value for every dollar we spend."
In addition, Actavis announced that Robert Stewart, president of global operations, will take on an expanded role of driving efficiencies across the organization, as well as harnessing the capabilities of Actavis' global manufacturing and distribution functions, including the continued oversight of Anda Inc. Marc Lehnen, senior vice president of global integration management ,and Patrick Eagan, chief human resources officer. will now report to Stewart.
Actavis markets generic, branded generic, legacy brands and OTC products in over 60 nations and operates a global branded specialty pharmaceutical business focused on the women's health, urology, gastroenterology and dermatology categories. The company also has a portfolio of five biosimilar products in development in women's health and oncology. Actavis' global operations encompasses more than 30 manufacturing and distribution facilities around the world, including Anda Inc., a U.S. pharmaceutical distributor.
Actavis has global headquarters in Dublin, Ireland, and U.S. administrative headquarters in Parsippany, N.J.